Daily Archives: March 7, 2019

Komet Files Initial Mineral Resource Technical Report for the Kabaya Prospect, (Dabia Sud property, Mali)

QUEBEC CITY, March 07, 2019 (GLOBE NEWSWIRE) — Komet Resources Inc. (TSX-V: KMT) (“Komet” or the “Company”) is pleased to announce today that a technical report, prepared in accordance with National Instrument 43–101 (“NI 43–101”), has been filed for the Kabaya Gold Resource, located in the southeastern part of the company’s Dabia Sud property, western Mali, West Africa (“the Report).

The report supports the disclosure made in Komet’s press release issued on January 21, 2019, entitled “Komet announces initial Mineral Resource Estimate for the Kabaya Prospect.”  There are no material differences in assumptions and estimates contained in the Report from those disclosed in the news release.

The report, dated March 5, 2019, is entitled “Dabia Sud Property, Kabaya Resource, NI 43–101 Technical Report, Mali” and was prepared by independent “Qualified Person” (as defined in NI 43–101) under the direction of Yann Camus, P.Eng., SGS Geological Services, Blainville, Canada. The report is available on SEDAR (www.sedar.com) and on the company’s website (kometgold.com).

Highlights of the Resource Estimate include:

  • An Indicated Resource of 3.17 million tonnes (Mt) grading 1.03 g/t for 105,000 contained gold ounces and an Inferred Resource of 0.96 Mt grading 1.14 g/t for 35,000 contained gold ounces at a cut-off grade of 0.40 g/t Au.
  • The pit constrained resource is based on optimized pit shells using a gold price of 1350 US$ and a presumed heap leach gold recovery of saprolite ore.
  • Gold mineralization at Kabaya remains open at depth in bedrock and laterally to the southwest and northwest.

Pit-constrained Indicated and Inferred Resources estimates as reported by SGS

Classification Tonnage (Mt) Au (g/t) Ounces (koz)
Indicated 3.17 1.03 105
Inferred 0.96 1.14 35
  1. Effective date for resources is January 7, 2019.
  2. The independent QP for this resource estimate is Yann Camus, Eng., SGS Canada Inc.
  3. The mineral resources are presented at a 0.4 g/t Au cut-off grade in pits.
  4. The resources are presented without dilution.
  5. Whittle pits have been utilized based on a gold value of US$1,350/oz.
  6. Mineral resources that are not mineral reserves do not have demonstrated economic viability. This disclosure does not include economic analysis of the mineral resources.
  7. No economic evaluation of the resources has been produced.
  8. This Resource Estimate has been prepared in accordance with CIM definition (2014).
  9. Density used is of 1.7 based on measurements and similar projects.
  10. Capping grade is of 30 g/t Au on original assays.

The Kabaya resource estimate is based on analytical data from trenching and several drill campaigns realized in 2012-2013-2014, 2017 and 2018. Five trenches, totalling 515 m, were realized in 2012–2013. All drilling was performed along east—west oriented lines with shallow drill holes inclined 50° to the west and consisted mainly of RC holes, totalling 12,530 m.

The independent qualified person for this Press Release, as defined by NI 43–101 guidelines, is Yann Camus P. Eng., of SGS Canada Inc. —Geological Services (“SGS Geological Services”), who has approved the technical information disclosed in this press release. The effective date of the technical report is January 7, 2019. Other scientific and technical content related to drilling in this news release is approved by Mr. Pascal van Osta, P.Geo., Vice President Exploration.

For more Information on Komet Resources Inc.:
Lucas Werner Claessens
Chief Executive Officer
Email: lw.claessens@kometgold.com
Tel: +1-647-647-2285

Investors relations:
Carl Desjardins, Relations publiques Paradox inc.
Email: carldesjardins@paradox-pr.ca
Tel: +1-514-341-0408

About Komet Resources
Komet Resources Inc. is a Canadian-based gold mining and exploration company, listed on the TSX-V, with a focus on exploration and production at its projects in Burkina Faso and Mali, West Africa.

Forward-looking Statements
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This press release contains statements that may constitute “forward-looking information” or “forward-looking statements” as set out within the context of security law. This forward-looking information is subject to many risks and uncertainties, some of which are beyond Komet’s control. The actual results or conclusions may differ considerably from those that have been set out, or intimated, in this forward-looking information. There are many factors which may cause such disparity, especially the instability of metal market prices, the results of fluctuations in foreign currency exchange rates or in interest rates, poorly estimated resources, environmental risks (stricter regulations), unforeseen geological situations, unfavourable extraction conditions, political risks brought on by mining in developing countries, regulatory and governmental policy changes (laws and policies), failure to obtain the requisite permits and approvals from government bodies, or any other risk relating to mining and development. There is no guarantee that the circumstances anticipated in this forward-looking information will occur, or if they do occur, how they will benefit Komet. The forward-looking information is based on the estimates and opinions of Komet’s management at the time of the publication of the information and Komet does not assume any obligation to make public updates or modifications to any of the forward-looking statements, whether as a result of new information, future events, or any other cause, except if it is required by securities laws.

Outstanding shares: 73,481,385

Crown Bioscience จับมือ The Jackson Laboratory ช่วยให้สามารถเข้าถึงแบบจำลองเมาส์ FATZO ได้ทั่วโลก

การทำงานร่วมกันอย่างต่อเนื่องจะช่วยให้โรคอ้วน โรคเกี่ยวกับระบบเผาผลาญ และแบบจำลอง NASH และการจัดลำดับความสำคัญกระจายไปยังแพลตฟอร์มระบบหัวใจ หลอดเลือดหัวใจ โรคอ้วนและโรคเกี่ยวกับการเผาผลาญของ CrownBio ได้ทั่วโลก

ซานดิเอโก, March 07, 2019 (GLOBE NEWSWIRE) — Crown Bioscience บริษัทผู้คิดค้นและพัฒนายาระดับโลกให้บริการแพลตฟอร์มการเคลื่อนที่แบบคงที่เพื่อการพัฒนาเกี่ยวกับโรคที่เกี่ยวกับเนื้องอกวิทยา การอักเสบ การเต้นของหัวใจและหลอดเลือดและระบบเผาผลาญได้ประกาศข้อตกลงพิเศษกับ The Jackson Laboratory (JAX) ในวันนี้ เพื่อใช้ช่องทางการจัดจำหน่ายระดับโลกในการสร้างแบบจำลองหนู FATZO สำหรับนักวิจัยทั่วโลก

ในฐานะผู้จัดจำหน่ายแบบจำลอง FATZO รุ่นพิเศษของ CrownBio JAX ซึ่งเป็นองค์กรวิจัยชีวการแพทย์อิสระที่ไม่แสวงหากำไรจะใช้ประโยชน์จากความเชี่ยวชาญในการผสมพันธุ์สัตว์ การผลิตและการส่งมอบแบบจำลองหนูคุณภาพสูงเพื่อเพิ่มการเข้าถึงทั่วโลกได้ทันที ในฐานะส่วนหนึ่งของข้อตกลง JAX จะจัดหารูปแบบการจัดลำดับความสำคัญเพื่อสนับสนุนแพลตฟอร์มบริการระดับโลกของ CrownBio ในโรคอ้วน เบาหวานและสิ่งบ่งชี้ที่เกี่ยวข้อง

รูปแบบที่เป็นเอกลักษณ์และเป็นกรรมสิทธิ์ของ CrownBio ซึ่งเป็นแบบจำลอง FATZO นั้นเป็นแบบจำลองหนูที่มีความเกี่ยวข้องกับการเคลื่อนที่ เหมาะสำหรับการศึกษาโรคอ้วน อาการของโรคที่เกี่ยวกับการเผาผลาญและเบาหวาน และการพัฒนายา แบบจำลองดังกล่าวมีความไวต่อการพัฒนาโรคอ้วนและกลุ่มอาการของโรคที่เกี่ยวกับการเผาผลาญภายใต้อิทธิพลของอาหารไขมันสูงซึ่งได้รับการแสดงให้เห็นว่าเป็นปัจจัยสำคัญในการพัฒนามนุษย์ของเงื่อนไขเหล่านี้ แบบจำลองนี้ยังแสดงให้เห็นถึงความก้าวหน้าของโรคที่คล้ายกับโรคที่เกิดในมนุษย์ ซึ่งทำให้แบบจำลองดังกล่าวเป็นตัวเลือกที่เหมาะสมที่สุดสำหรับการจำลองอาการของโรคที่เกี่ยวกับระบบเผาผลาญของมนุษย์

นายแพทย์ Jim Wang รองประธานอาวุโสแผนกโรคหัวใจและหลอดเลือดและระบบเผาผลาญของ CrownBio กล่าวว่า “ผมรู้สึกตื่นเต้นที่ความสัมพันธ์อย่างต่อเนื่องของเรากับ The Jackson Laboratory ผลักดันให้เกิดข้อตกลงนี้ และจะช่วยให้เข้าถึง FATZO ได้ง่ายขึ้น ซึ่งจะช่วยเร่งการค้นพบโรคอ้วนเบาหวานและ NAFLD / NASH”

หากต้องการเรียนรู้เพิ่มเติมเกี่ยวกับหนู FATZO และแพลตฟอร์มโรคหัวใจและหลอดเลือดและการเผาผลาญของ Crown ให้ไปที่: www.crownbio.com/cvmd

เกี่ยวกับบริษัท Crown Bioscience

Crown Bioscience เป็นบริษัทผู้ให้บริการด้านการค้นคว้าและพัฒนายาระดับโลกที่ให้บริการแพลตฟอร์มการแปลเพื่อความก้าวหน้าด้านเนื้องอกวิทยาและการวิจัยโรคที่เกี่ยวกับระบบเผาผลาญ ด้วยผลงานที่ครอบคลุมเกี่ยวกับแบบจำลองและเครื่องมือการคาดการณ์ที่เกี่ยวข้อง Crown Bioscience จึงทำให้ลูกค้าสามารถมอบการรักษาที่เหมาะสมได้อย่างเหนือชั้

ช่องทางสอบถามสำหรับสื่อ:
Jody Barbeau
Crown Bioscience Inc.
marketing@crownbio.com

Grace Scott
The Jackson Laboratory
news@jax.org

Philips global sleep survey shows we want better sleep, but only if it comes easily

  • 44% of adults surveyed globally admit their sleep has worsened in the last five years
  • 8 in 10 adults worldwide want to improve the quality of their sleep, but the majority (60%) have not sought help from a medical professional

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the findings from its annual global sleep survey in a report, “The Global Pursuit of Better Sleep Health”. The survey, executed each year in recognition of World Sleep Day (March 15), surveyed adults in 12 countries to capture attitudes, perceptions, and behaviors around sleep. Results showed that while awareness of sleep’s impact on overall health is on the rise, for many across the globe, achieving quality sleep health remains elusive.

Despite 77% of surveyed adults recognizing that sleep has an impact on health, 62% admitted they sleep only somewhat well and 44% stated that their sleep has worsened in the past five years. According to the Centers for Disease Control and Prevention, about 70 million Americans suffer from chronic sleep problems [1] and poor sleep health resulting in sleep deprivation, which has a high correlation to depression, obesity, diabetes, heart disease, stroke, neurocognitive disease, and even cancer [2].

The survey, executed by KJT Group on behalf of Philips, interviewed 11,006 respondents in Australia, Brazil, Canada, China, France, Germany, India, Japan, Netherlands, Singapore, South Korea, and the United States. The findings showed that most respondents would rather consult the Internet than a physician when it comes to sleep-related issues. Eight in 10 global adults want to improve the quality of their sleep, but the majority (60%) have not sought help from a medical professional. When struggling with sleep issues, those surveyed said they’re also most likely to turn to online information sources for their sleep concerns. Even more concerning, 65% of those who reported having sleep apnea have either never used or are no longer using sleep apnea therapy to treat their disease.

“This data suggests that while people are waking up to the reality that sleep is fundamentally important, for most people, achieving quality sleep is still out of reach,” said Mark Aloia, PhD, Global Lead for Behavior Change, Sleep & Respiratory Care at Philips. “If we want to take sleep seriously and address the social and emotional aspects of poor sleep, we must begin to demonstrate that we can address these problems in both easy and meaningful ways that are supported by strong clinical science. Part of what we’re working towards at Philips is evolving our offering of clinically-validated solutions with a hope of addressing 80% of sleep issues across the globe in the near future. The hope is that people who have struggled with varieties of sleep issues for so long will have options available to them to sleep and live better.”

The survey also found that 76% of adults surveyed globally experience at least one listed condition that impacts their sleep, with insomnia (37%) and snoring (29%) being the most common, an increase from the 2018 survey which showed 26% reporting insomnia, and 21% reporting snoring, respectively. With so many potential factors impacting a good night’s rest, Philips aims to use this data to help people across the globe understand not only the value of sleep, but how to start improving their sleep habits.

For more insight from this year’s survey, please visit please click here. To view additional findings from this year or last year’s global survey, visit: Philips.com/WorldSleepDay.

Philips is deeply rooted in its commitment to developing clinically-proven solutions that help people take control of their sleep health. Philips aims to provide solutions that meet the growing and evolving needs of consumers and healthcare professionals alike, most recently with its expansion of the SmartSleep suite of solutions and its surpassing of ten million DreamWear masks and cushions sold worldwide. For more information on Philips’ advanced solutions for sleep and respiratory care, follow @PhilipsSleepWellness, @PhilipsResp or visit www.Philips.com/SmartSleep.

[1] https://www.cdc.gov/sleep/about_us.html
[2] https://www.ncbi.nlm.nih.gov/books/NBK19961/

For further information, please contact:

Kathy O’Reilly
Philips Group Press Office
Mobile: +1 978-221-8919
E-mail: kathy.oreilly@philips.com

Meredith Amoroso
Philips Sleep and Respiratory Care
Mobile: +1 724-584-8991
E-mail: meredith.amoroso@philips.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2018 sales of EUR 18.1 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

About the Survey
This survey was conducted online by KJT Group on behalf of Philips from January 9 – January 28, 2019 among 11,006 adults ages 18 and older in 12 countries (Australia: n=750; Brazil: n=1,001; Canada: n=750: China, n=1,001: France: n=1,000; Germany: n=1,003; India: n=1,000; Japan: n=1,000; Netherlands: n=750; Singapore: 750; South Korea: n=1,000 and the U.S.: n=1,000). The survey was web-based and self-administered in the primary language(s) of each country. These were non-probability samples and thus a margin of error cannot be accurately estimated. For complete survey methodology, including weighting variables, please contact Meredith Amoroso at meredith.amoroso@philips.com.

Attachments

Helsinn initiates two new global Phase III studies with anamorelin

Helsinn initiates two new global Phase III studies with anamorelin

  • Helsinn committed to anamorelin which is being evaluated for weight loss and anorexia in patients with advanced non small cell lung cancer (NSCLC) and cachexia
  • ONO has submitted application for manufacturing and marketing approval of anamorelin in Japan

LUGANO, Switzerland, March 7, 2019: Helsinn Group, a Swiss pharmaceutical group focused on building quality cancer care products, today announces that the first patient has now been dosed in the new global Phase III program to evaluate anamorelin for the treatment of weight loss and anorexia in patients with advanced NSCLC with cachexia. Cancer cachexia is a multifactorial syndrome that involves loss of muscle mass and body weight, and is often accompanied by anorexia/loss of appetite.
Anamorelin is an orally active selective ghrelin receptor agonist which activates multiple pathways involved in the positive regulation of appetite and body weight.
The Phase III program consists of two 24-week double-blind randomized placebo-controlled multiregional confirmatory trials with identical study design. The primary efficacy endpoint will be measured at week 9 and will be based on the concomitant occurrence of a clinically relevant improvement of both body weight and a validated PRO (5-item Anorexia Symptoms Scale score) in alive patients at Day 64.
Riccardo Braglia, Helsinn Group Vice Chairman and CEO, said: “I am excited that the new Phase III program with anamorelin is taking off. Several clinical studies have clearly indicated that anamorelin had demonstrated an effect in weight loss and anorexia, two major components of cancer-cachexia, and Helsinn is fully committed to continue all the necessary development activities to bring this agent to cancer patients. Cancer cachexia remains an area of largely unsatisfied medical need with no safe and effective pharmacologic treatments available. Anamorelin could represent an innovative treatment for this currently high unmet cancer supportive care.”
“We’re delighted also that Ono Pharmaceutical Co., Ltd., our Japanese partner, has recently submitted an application for the manufacturing and marketing approval of anamorelin (ONO-7643) in Japan, a step we believe brings this promising therapy closer to the patients that need it.”

Anamorelin is an investigational agent not approved in any country.

Anamorelin in Japan
The application in Japan is mainly based on the results from the following two studies conducted in Japan in patients with cancer-cachexia:

  • Phase II multi-center, placebo-controlled, randomized, double-blind, parallel group study in patients with non-small cell lung cancer (ONO-7643-04 study),
  • Phase III multi-center, open-label, uncontrolled study in patients with colorectal, gastric or pancreatic cancer (ONO-7643-05 study).

In accordance with a license agreement with Ono Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd. has exclusive rights to develop and commercialize anamorelin in Japan, South Korea, and Taiwan.

About Anamorelin
Anamorelin is a selective, novel, orally active ghrelin receptor agonist. Ghrelin is an endogenous peptide primarily secreted by the stomach. Upon binding to its receptor, ghrelin stimulates multiple pathways in the positive regulation of body weight, muscle mass, appetite and metabolism. Anamorelin has shown effects in increasing body weight, and muscle mass, as well as appetite in patients with cancer cachexia and is expected to be the first treatment for this patient population.

About the Helsinn Group

Helsinn is a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Switzerland, Ireland, the U.S., Monaco and China, as well as a product presence in approximately 190 countries globally.
To learn more about Helsinn Group please visit www.helsinn.com

For more information:

Helsinn Group
Paola Bonvicini

Group Head of Communication

Lugano, Switzerland

Tel: +41 (0) 91 985 21 21

Info-hhc@helsinn.com

For more information, please visit www.helsinn.com and follow us on Twitter, LinkedIn and Vimeo

ANAM-US-0010